Skip to Main Content

Paper Details

ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels.
Arteriosclerosis, Thrombosis, and Vascular Biology
43
2017
ABCA8, ABCA8 mutations, Abca8b, Abca8b-/-, CONCLUSIONS ABCA8, Cholesterol, HDL, HDL cholesterol, HDLc, High, High-Density Lipoprotein Cholesterol, High-density lipoproteins, IVS17, Pro609Arg, adenosine triphosphate, adenosine triphosphate-binding cassette transporter A1, adenosine triphosphate-binding cassette transporter A8, apolipoprotein AI, atherosclerosis, cholesterol, human, human ABCA8, humans, macrophage, mice, mutant ABCA8
Author NameAffiliation
Liang Juin TanA STAR Institute, and Yong Loo Lin School of Medicine, National University of Singapore (L.T.-M., Academic Medical Centre, University of Amsterdam, Simon Fraser University, Yong Loo Lin School of Medicine, National University of Singapore (F.T., M.R.W.) Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute, University of British Columbia, University Medical Center Groningen, University of Groningen, U.J.F.T.) Xenon Pharmaceuticals, National University of Singapore (C.H.T., Center for Brain Research, Medical University of Vienna, J.B.) Beaulieu-Saucier Universite de Montreal Pharmacogenomics Centre, M.-P.D.) Montreal Heart Institute Research Centre, M.-P.D.) and Universite de Montreal
Michael R HaydenA STAR Institute, and Yong Loo Lin School of Medicine, National University of Singapore (L.T.-M., Academic Medical Centre, University of Amsterdam, Simon Fraser University, Yong Loo Lin School of Medicine, National University of Singapore (F.T., M.R.W.) Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute, University of British Columbia, University Medical Center Groningen, University of Groningen, U.J.F.T.) Xenon Pharmaceuticals, National University of Singapore (C.H.T., Center for Brain Research, Medical University of Vienna, J.B.) Beaulieu-Saucier Universite de Montreal Pharmacogenomics Centre, M.-P.D.) Montreal Heart Institute Research Centre, M.-P.D.) and Universite de Montreal
Gerard K HovinghA STAR Institute, and Yong Loo Lin School of Medicine, National University of Singapore (L.T.-M., Academic Medical Centre, University of Amsterdam, Simon Fraser University, Yong Loo Lin School of Medicine, National University of Singapore (F.T., M.R.W.) Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute, University of British Columbia, University Medical Center Groningen, University of Groningen, U.J.F.T.) Xenon Pharmaceuticals, National University of Singapore (C.H.T., Center for Brain Research, Medical University of Vienna, J.B.) Beaulieu-Saucier Universite de Montreal Pharmacogenomics Centre, M.-P.D.) Montreal Heart Institute Research Centre, M.-P.D.) and Universite de Montreal
Roshni R SingarajaA STAR Institute, and Yong Loo Lin School of Medicine, National University of Singapore (L.T.-M., Academic Medical Centre, University of Amsterdam, Simon Fraser University, Yong Loo Lin School of Medicine, National University of Singapore (F.T., M.R.W.) Centre for Molecular Medicine and Therapeutics and Child and Family Research Institute, University of British Columbia, University Medical Center Groningen, University of Groningen, U.J.F.T.) Xenon Pharmaceuticals, National University of Singapore (C.H.T., Center for Brain Research, Medical University of Vienna, J.B.) Beaulieu-Saucier Universite de Montreal Pharmacogenomics Centre, M.-P.D.) Montreal Heart Institute Research Centre, M.-P.D.) and Universite de Montreal
  • 1 - 4

Datasets

Release 1.2